Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27484870 | 1.00 | DNM1 (0.57) | — | |
| Hydrochloric Acid SCHEMBL3331972 | 1.00 | — | — | |
| SCHEMBL345699 | 0.96 | — | — | |
| SCHEMBL3002135 | 0.96 | — | — | |
| SCHEMBL28836736 | 0.96 | DNM1 (0.61) | — | |
| SCHEMBL7516444 | 0.96 | DNM1 (0.61) | — | |
| SCHEMBL5554848 | 0.96 | DNM1 (0.61) | — | |
| SCHEMBL1695732 | 0.96 | — | — | |
| SCHEMBL4373470 | 0.96 | DNM1 (0.61) | — | |
| SCHEMBL19037263 | 0.96 | DNM1 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721759-A1 | LIPID NANOPARTICLE FOR DELIVERING NUCLEIC ACID DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Cansino (Shanghai) Biological Research Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| EP-4707289-A1 | STEROID-CATIONIC LIPID COMPOUND AND USE THEREOF | Cansino (Shanghai) Biological Research Co., Ltd. (CN) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024227433-A1 | LIPID NANOPARTICLE FOR DELIVERING NUCLEIC ACID DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 康希诺(上海)生物研发有限公司 | 2024-11-07 | — | — | WO | disclosed |
| WO-2024227430-A1 | STEROID-CATIONIC LIPID COMPOUND AND USE THEREOF | 康希诺(上海)生物研发有限公司 | 2024-11-07 | — | — | WO | disclosed |
| CN-118845700-A | Lipid nanoparticle for delivering nucleic acid drug, preparation method and application thereof | 康希诺(上海)生物研发有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118852306-A | Steroid-cationic lipid compound and application thereof | 康希诺(上海)生物研发有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-3353161-B1 | TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS | US HEALTH (US) | 2021-07-21 | — | — | EP | disclosed |
| CN-107952082-B | Multifunctional synergistic pharmaceutical composition based on adriamycin and construction method thereof | 中国药科大学 | 2021-07-13 | — | — | CN | disclosed |
| EP-3253764-B1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-06-09 | — | — | EP | disclosed |
| CN-107849055-B | Macrocyclic compounds useful as IRAK1/4 inhibitors and uses thereof | 默克专利有限公司 | 2020-08-07 | — | — | CN | disclosed |
| US-9815836-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-20170275284-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-9708324-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| WO-2017053769-A1 | TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2016127025-A1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
| US-20160229856-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20130243720-A1 | Iron(II)-Containing A Treatments for Hyperphosphatemia | HUVAL CHAD (US) | 2013-09-19 | — | — | US | disclosed |
| US-20100135950-A1 | Iron(II)-Containing Treatments for Hyperphosphatemia | GENZYME CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2043627-A2 | IRON(II)-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA | Genzyme Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005217-A2 | IRON(II)-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA | GENZYME CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |